Regeneron Pharmaceuticals (REGN) Stock Forecast & Price Target

$1,131.50

-19.06 (-1.66%)

(As of 09/6/2024 ET)

Regeneron Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy
Based on 21 Analyst Ratings

Based on 21 Wall Street analysts who have issued ratings for Regeneron Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 21 analysts, 1 has given a sell rating, 3 have given a hold rating, 16 have given a buy rating, and 1 has given a strong buy rating for REGN.

Consensus Price Target

$1,108.95
-1.99% Downside

High Forecast	$1,300.00
Average Forecast	$1,108.95
Low Forecast	$720.00

According to the 21 analysts' twelve-month price targets for Regeneron Pharmaceuticals, the average price target is $1,108.95. The highest price target for REGN is $1,300.00, while the lowest price target for REGN is $720.00. The average price target represents a forecasted downside of -1.99% from the current price of $1,131.50.

Type	Current Forecast 9/9/23 to 9/8/24	1 Month Ago 8/10/23 to 8/9/24	3 Months Ago 6/11/23 to 6/10/24	1 Year Ago 9/9/22 to 9/9/23
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	16 Buy rating(s)	17 Buy rating(s)	15 Buy rating(s)	19 Buy rating(s)
Hold	3 Hold rating(s)	4 Hold rating(s)	4 Hold rating(s)	4 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$1,108.95	$1,097.05	$989.86	$903.27
Forecasted Upside	-1.99% Downside	11.16% Upside	12.54% Upside	14.75% Upside

Get Regeneron Pharmaceuticals Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for REGN and its competitors with MarketBeat's FREE daily newsletter.

Ad Weiss Ratings

“Fed Proof” Your Bank Account with THESE 4 Simple Steps

Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.

Learn these 4 simple steps and protect your savings before it’s too late.

REGN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

REGN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Regeneron Pharmaceuticals Stock vs. The Competition

Type	Regeneron Pharmaceuticals	Medical Companies	S&P 500
Consensus Rating Score	2.81	2.77	2.51
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	-1.99% Downside	1,204.87% Upside	11.37% Upside
News Sentiment Rating	Positive News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
9/5/2024	Royal Bank of Canada 4 of 5 stars		Reiterated Rating	Outperform ➝ Outperform	$1,250.00 ➝ $1,250.00	+8.38%
8/23/2024	Piper Sandler 2 of 5 stars		Boost Target	Overweight ➝ Overweight	$1,166.00 ➝ $1,242.00	+3.39%
8/2/2024	JPMorgan Chase & Co. 3 of 5 stars		Boost Target	Overweight ➝ Overweight	$1,150.00 ➝ $1,200.00	+10.89%
8/2/2024	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$1,180.00 ➝ $1,300.00	+19.90%
8/2/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$1,125.00 ➝ $1,200.00	+10.49%
8/2/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$1,200.00 ➝ $1,220.00	+12.61%
Get the Latest News and Ratings for REGN and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.
8/2/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$1,135.00 ➝ $1,200.00	+9.78%
7/23/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$1,030.00 ➝ $1,200.00	+12.39%
7/22/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$925.00 ➝ $1,000.00	-6.21%
7/11/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$1,183.00 ➝ $1,182.00	+8.81%
6/27/2024	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$1,152.00 ➝ $1,152.00	+7.78%
6/25/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$1,060.00 ➝ $1,170.00	+9.97%
5/14/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$1,150.00	+17.71%
4/17/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$1,090.00 ➝ $1,099.00	+21.95%
4/12/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Underperform ➝ Underperform	$710.00 ➝ $720.00	-21.77%
3/12/2024	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$1,125.00	+16.65%
2/5/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$1,055.00 ➝ $1,082.00	+14.48%
11/28/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$935.00 ➝ $937.00	+17.00%
11/9/2023	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Hold	$800.00	-2.77%
11/3/2023	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Market Perform ➝ Outperform	$950.00	+16.02%
9/15/2023	Westpark Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Hold
8/21/2023	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Market Perform	$950.00 ➝ $1,050.00	+29.25%
6/28/2023	22nd Century Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Downgrade
6/28/2023	500.com Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Maintains
6/28/2023	VNET Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Downgrade
6/28/2023	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$800.00 ➝ $760.00	+6.13%
5/5/2023	888 Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Maintains
5/5/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$976.00 ➝ $895.00	+17.59%
3/28/2023	Erste Group Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy
3/27/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Risinger Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform
3/23/2023	EF Hutton Acquisition Co. I Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy	$853.00 ➝ $862.00	+14.73%
1/30/2023	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Market Perform ➝ Outperform	$775.00 ➝ $875.00	+17.79%
10/3/2022	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy	$796.00 ➝ $970.00	+32.49%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 06:36 AM ET.

REGN Forecast - Frequently Asked Questions

What is Regeneron Pharmaceuticals' forecast for 2024?: According to the research reports of 21 Wall Street equities research analysts, the average twelve-month stock price forecast for Regeneron Pharmaceuticals is $1,108.95, with a high forecast of $1,300.00 and a low forecast of $720.00.
Should I buy or sell Regeneron Pharmaceuticals stock right now?: 21 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last twelve months. There is currently 1 sell rating, 3 hold ratings, 16 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" REGN shares.
Does Regeneron Pharmaceuticals's stock price have much upside?: According to analysts, Regeneron Pharmaceuticals's stock has a predicted upside of 9.22% based on their 12-month stock forecasts.
What analysts cover Regeneron Pharmaceuticals?: Regeneron Pharmaceuticals has been rated by research analysts at Argus, Barclays, Canaccord Genuity Group, Cantor Fitzgerald, Guggenheim, JPMorgan Chase & Co., Morgan Stanley, Piper Sandler, Royal Bank of Canada, TD Cowen, Truist Financial, and Wells Fargo & Company in the past 90 days.
Do Wall Street analysts like Regeneron Pharmaceuticals more than its competitors?: Analysts like Regeneron Pharmaceuticals more than other "medical" companies. The consensus rating score for Regeneron Pharmaceuticals is 2.81 while the average consensus rating score for "medical" companies is 2.77. Learn more on how REGN compares to other companies.